 A STUDY OF PARTICIPANT PREFERENCE WITH SUBCUTANEOUS VERSUS INTRAVENOUS MABTHERARITUXAN IN PARTICIPANTS WITH CD20 DIFFUSE LARGE B-CELL LYMPHOMA OR CD20 FOLLICULAR NON-HODGKINS LYMPHOMA GRADES 1, 2 OR 3A: 